3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-6-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-6-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride
• 化学式: C25H28ClN3O5
• 分子量: 486.0
• InChiKey: RLZHFFVOKCKGTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.85
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  88.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS<br/>[FR] 3-(4-((4-(MORPHOLINOMÉTHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE POUR LE TRAITEMENT DU LUPUS ÉRYTHÉMATEUX SYSTÉMIQUE
  申请人：CELGENE CORP

  公开号：WO2015179276A1

  公开（公告）日：2015-11-26

  Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

  本文提供了使用化合物和组合物治疗、管理和/或预防系统性红斑狼疮（SLE）的方法。本文还提供了用于这些方法的药物组合和用药方案。
• TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES
  申请人：Celgene Corporation

  公开号：EP2882441A2

  公开（公告）日：2015-06-17
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：EP2935226A1

  公开（公告）日：2015-10-28
• 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
  申请人：Celgene Corporation

  公开号：EP3145513A1

  公开（公告）日：2017-03-29
• [EN] TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES<br/>[FR] TRAITEMENT DES MALADIES INFLAMMATOIRES ET ASSOCIÉES À L'IMMUNITÉ
  申请人：CELGENE CORP

  公开号：WO2014025958A2

  公开（公告）日：2014-02-13

  Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.